|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||||
  European Journal of NeurologyVolume 14 Issue 6, Pages 701 - 703 Published Online: 29 May 2007 Journal compilation © 2010 European Federation of Neurological Societies The Official Journal of the European Federation of Neurological Societies (EFNS)
Abstract | References | Full Text: HTML, PDF (Size: 499K) | Related Articles | Citation Tracking  SHORT COMMUNICATION Efficacy of lisinopril in migraine prophylaxis – an open label study Copyright 2007 EFNS KEYWORDS angiotensin converting enzyme • lisinopril • migraine • prophylaxis ABSTRACTThe ACE-inhibitor lisinopril has previously been shown to be effective in migraine prophylaxis at a daily dose of 20 mg. To test the effect of a low dose of lisinopril (5 mg daily) in migraine prevention, we performed an open label study in 21 migraineurs. The primary outcome measure was frequency of migraine attacks. Secondary efficacy measures were migraine hours, intake of acute migraine drugs, pain intensity and responder rate. Compared with baseline conditions, the attack frequency of migraine attacks was significantly reduced (P < 0.0005). The number of acute migraine drugs dropped significantly (P = 0.002). Three patients dropped out because of intolerable cough. Our study suggests that even low doses of lisinopril may be effective in migraine treatment. However, its use may be limited by intolerable side-effects. Received 4 August 2006 Accepted 19 January 2007 | 
|
